SummaryBackgroundPlasmodium vivaxmalaria is challenging to control and eliminate. Treatment with radical cure drugs fails to target the hidden asymptomatic and hypnozoite reservoirs in populations.PvSeroTAT, a novel serological test-and-treat intervention using a serological diagnostic to screen hypnozoite carriers for radical cure eligibility and treatment, could accelerateP. vivaxelimination.MethodsUsing a previously developed mathematical model ofP. vivaxtransmission adapted to the Brazilian context as a case study for implementation, we evaluate the public health impact of various deployment strategies ofPvSeroTAT as a mass campaign. We compare relative reductions in prevalence, cases averted, glucose-6-phosphate dehydrogenase (G6PD) tests, and treatment doses ofPvSeroTAT campaigns to strengthened case management alone or mass drug administration (MDA) campaigns across different settings.FindingsDeploying a single round ofPvSeroTAT with 80% coverage to treat cases with a high efficacy radical cure regimen with primaquine is predicted to reduce point population prevalence by 22.5% [95% UI: 20.2%–24.8%] in a peri-urban setting with high transmission and by 25.2% [95% UI: 9.6%–42.2%] in an occupational setting with moderate transmission. In the latter example, while a singlePvSeroTAT achieves 9.2% less impact on prevalence and averts 300 less cases per 100,000 than a single MDA (25.2% [95% UI: 9.6%–42.2%] point prevalence reduction versus 34.4% [95% UI: 24.9%–44%]),PvSeroTAT requires 4.6 times less radical cure treatments and G6PD tests. Layering strengthened case management and deploying four rounds ofPvSeroTAT six months apart is predicted to reduce point prevalence by a mean of 74.1% [95% UI: 61.3%–86.3%] or more in low transmission settings with less than 10 cases per 1000 population.InterpretationModelling predicts that mass campaigns withPvSeroTAT are predicted to reduceP. vivaxparasite prevalence across a range of transmission settings and require fewer resources than MDA. In combination with strengthened case management, mass campaigns of serological test-and-treat interventions can accelerate towardsP. vivaxelimination.FundingThis project was funded in part by the10.13039/100000865Bill and Melinda Gates Foundationand the10.13039/501100000925National Health and Medical Research Council.